Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation

Bone Marrow Transplant. 2016 Mar;51(3):443-5. doi: 10.1038/bmt.2015.266. Epub 2015 Nov 9.

Authors

L Angenendt¹, C Schliemann¹, M Lutz¹, E Rebber¹, A B Schulze¹, M Weckesser², L Stegger², M Schäfers², C Groth¹, T Kessler¹, G Lenz¹, M Stelljes¹, W E Berdel¹

Affiliations

¹ Department of Medicine A, Hematology & Oncology, University Hospital Muenster, Muenster, Germany.
² Department of Nuclear Medicine, University Hospital Muenster, Muenster, Germany.

PMID: 26551782
DOI: 10.1038/bmt.2015.266

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adolescent
Allografts
Antibodies, Monoclonal / administration & dosage*
Hodgkin Disease / diagnostic imaging
Hodgkin Disease / therapy*
Humans
Male
Nivolumab
Recurrence
Stem Cell Transplantation*

Substances

Antibodies, Monoclonal
Nivolumab